-
A&D Medical launches Wellness Connected platform
LAS VEGAS — A&D Medical on Tuesday announced the release of its next generation Wellness Connected, a secure, flexible platform to help people increase physical activity and manage their health.
“Designed to address the demands of corporate and consumer wellness markets, the Wellness Connected platform combines the company’s new Bluetooth Smart-enabled medical devices, A&D Connect mobile app and cloud service to give individuals and organizations the tools they need to track progress toward healthy living goals.
-
FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said Wednesday.
The FDA announced the approval of Farxiga (dapagliflozin) tablets, designed for use with exercise and dietary adjustments to control blood sugar. Type 2 diabetes affects about 24 million people in the United States, accounting for more than 90% of diabetes cases.